Spark Therapeutics is engaged in the field of gene therapy. Co. has built a pipeline of gene therapy product candidates that are directed to the retina, the liver and the central nervous system. Co.'s product, LUXTURNA™ (voretigene neparvovec-rzyl), has been approved by the U.S. Food and Drug Administration for the treatment of patients with viable retinal cells and confirmed biallelic RPE65 mutation-associated retinal dystrophy. Co.'s gene therapy product candidates in clinical development include: SPK-8011, Co.'s primary product candidate in the SPK-FVIII program for hemophilia A; SPK-8016, a product candidate for the hemophilia A inhibitor market; and SPK-7001, targeting choroideremia. The ONCE average annual return 10 years is shown above.
The Average Annual Return on the ONCE average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ONCE average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ONCE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
